Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel SyndromeSummary

Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel SyndromeSummary

Background & Aims: Options for the prevention of short-bowel syndromeâassociated liver disease (SBS-ALDs) are limited and often ineffective. The farnesoid X receptor (FXR) is a newly emerging pharmaceutical target and FXR agonists have been shown to ameliorate cholestasis and metabolic disorders...

Full description

Bibliographic Details
Main Authors: Prue M. Pereira-Fantini, Susan Lapthorne, Cormac G.M. Gahan, Susan A. Joyce, Jenny Charles, Peter J. Fuller, Julie E. Bines
Format: Article
Language:English
Published: Elsevier 2017-07-01
Series:Cellular and Molecular Gastroenterology and Hepatology
Online Access:http://www.sciencedirect.com/science/article/pii/S2352345X17300413

Similar Items

Similar Items